ArticleUrology2018
The Receipt of Industry Payments is Associated With Prescribing Promoted Alpha-blockers and Overactive Bladder Medications.
Article in Urology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Are Financial Payments From the Pharmaceutical Industry Associated With Physician Prescribing? : A Systematic Review.Annals of internal medicine · 2021Pooled it
- Pharmaceutical marketing and patient trust: How do doctor-targeted campaigns affect patients?PloS one · 2026Article
- Managing Your Risk: Contemporary Ethical Issues in Urology.AUA update series · 2025Article
- Industry Payments for Vibegron and Prescribing Patterns Among Urologic Clinicians.JAMA health forum · 2023Article
- Article
- Evaluation of non-research payments from pharmaceutical companies to urologists in Japan between 2016 and 2019.International urogynecology journal · 2023Article
- Associations Between Industry Payments to Physicians for Antiplatelet Drugs and Utilization of Cardiac Procedures and Stents.Journal of general internal medicine · 2022Article
- Nature and Trends in Personal Payments Made to the Respiratory Physicians by Pharmaceutical Companies in Japan between 2016 and 2019.Respiration; international review of thoracic diseases · 2022Article
- Increasing Financial Payments From Industry to Medical Oncologists in the United States, 2014-2017.Journal of the National Comprehensive Cancer Network : JNCCN · 2021Article
- Association between physician characteristics and payments from industry in 2015-2017: observational study.BMJ open · 2019Observational
- Evaluating the Strength of the Association Between Industry Payments and Prescribing Practices in Oncology.The oncologist · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
objectiveTo determine the impact of physicians' financial relationships with the pharmaceutical industry on prescribing marketed alpha-blockers and overactive bladder (OAB) medications. We also aim to examine if the number or total value of transactions is influential. MATERIALS AND
methodsWe linked the Open Payments Program database of industry payments to prescribers with Medicare Part D prescription data. We used binomial logistic regression to identify the association between receipt of industry payment and prescribing of marketed alpha-blockers (silodosin) and OAB medications (fesoterodine, solifenacin, and mirabegron). We also evaluated the impact of increasing total value and number of payments on prescribing of marketed drugs.
resultsThe receipt of industry payment was associated with increased odds of prescribing the marketed drug for all included drugs: silodosin (odds ratio [OR] 34.1), fesoterodine (OR 5.9), solifenacin (OR 2.7), and mirabegron (OR 6.8) (all P <.001). We also found that increasing value of total payment and increasing frequency of payments were both independently associated with increased odds of prescribing with a dose-response effect.
conclusionThere is a consistent association between receipt of industry payment and prescribing marketed alpha-blockers and OAB medications. Both the total value and number of transactions were associated with prescribing.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.